Not long after a Series C fundraising in June this year, Everest Medicine initiated a public listing, marking a further strategic move for the biotech firm.
Mount Everest. Image credit: Andreas Gabler/Unsplash
Everest Medicines, the Zhejiang-based biotech startup, applied for an IPO on the Hong Kong Stock Exchange, only one month after a Series C fundraising of USD 310 million.
As an in-licensing biopharmaceutical company, Everest Medicines focuses on developing and commercializing innovative medicines. The product portfolio covers oncology, immunotherapy, infectious diseases and heart /kidney diseases.
Years of clinical trials have brought considerable losses – the year of 2019 recorded a loss as much of as much as CNY 176 million. Furthermore, the company already suffered a CNY 150 million loss in the first quarter of 2020.
However, a bright future may be on its way. Many pilot products have already entered Phase III – the critical stage in the clinical trial process. With rich experience in licensing and commercialization, the company looks likely to realize profits very soon.
The First Move of the U.S. Postal Service on Cross-Border E-commerce After Trump
Feb 21, 2025 08:19 PM
Shanghai and Shenzhen: The Dual-City Landscape and Corporate Power
Jan 09, 2025 03:35 PM